uniQure NV (NASDAQ:QURE) shares shot up 3.3% during trading on Friday . The stock traded as high as $7.66 and last traded at $7.59, with a volume of 186,997 shares. The stock had previously closed at $7.35.

Several brokerages recently commented on QURE. Leerink Swann reaffirmed a “buy” rating on shares of uniQure NV in a research note on Sunday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of uniQure NV in a research note on Thursday, June 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 target price on shares of uniQure NV in a research note on Wednesday, May 11th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $23.00 target price (down from $50.00) on shares of uniQure NV in a research note on Tuesday, April 5th. Finally, WallachBeth Capital decreased their target price on shares of uniQure NV from $60.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, June 15th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. uniQure NV has a consensus rating of “Buy” and a consensus target price of $30.80.

The firm’s market cap is $185.89 million. The firm has a 50 day moving average price of $9.49 and a 200-day moving average price of $12.98.

uniQure NV (NASDAQ:QURE) last posted its earnings results on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. On average, analysts anticipate that uniQure NV will post ($3.14) earnings per share for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.